C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€9.74M
Enterprise Value-€2.01
Total Cash (Recent Filing)€8.23M
Total Debt (Recent Filing)€2.03M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.26
Shares Outstanding5,278,957
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
Regulatory Clinical ProgressCompleting a >1,400 patient upper‑respiratory study materially reduces clinical and regulatory execution risk versus earlier stages. A targeted 510(k) submission and CLIA‑waived point‑of‑care pathway can unlock faster market access and durable commercial runway if clearance is achieved and maintained.
Established India Manufacturing & Market FootprintAn in‑market commercial presence with multiple CDSCO clearances and instrument manufacturing rights provides durable access to a large South Asia TAM. This lowers regulatory barriers, shortens commercialization cycles in the region, and creates a repeatable revenue base tied to local labs and procurement channels.
Manufacturing Scale And AutomationInvesting in automated consumable production that can cut manual steps ~4x improves unit economics and reliability. Once operational, higher throughput and lower per‑unit overhead support margin recovery and scalable supply for commercialization and larger studies over the coming months.
Bears Say
Liquidity And Funding RiskLow cash relative to ongoing operating losses creates a persistent funding requirement. Needing new capital risks dilution, restrictive financing terms, or execution delays for regulatory filings and manufacturing scale‑up. This is a durable constraint until sustainable cash generation or secured funding arrives.
Collapsed Revenue And Negative Unit EconomicsA tiny revenue base plus a recent gross loss indicate current unit economics and scale are insufficient to cover costs. Without steady, sizable revenue growth and improved gross margins, operating leverage cannot be realized, making profitable commercialization and self‑funding unlikely in the near term.
Balance‑sheet Erosion And Negative Cash GenerationMaterial equity erosion over several years signals cumulative losses and weak capital efficiency. With returns on equity negative and operating cash flow turned strongly negative historically, the company faces structural pressure to rebuild capital or secure transformative funding, raising long‑term financial fragility.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €9.74M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on May 14, 2026. The company reported -€3.566 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Overvalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 5,278,957 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€3.566 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
―
Heart Test Laboratories, Inc.
―